Telomir Pharmaceuticals, Inc.

The momentum for this stock is not very good. Telomir Pharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Telomir Pharmaceuticals, Inc..

News

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Accesswire MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ('Telomir' or the 'Company'), a pre-clinical-stage company seeking to lead developments in longevity science...\n more…

Telomir Pharmaceuticals's Telomir-1 featured in local ABC exclusive

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Accesswire Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior DogsTAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO...\n more…

TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nTelomir Pharmaceuticals just reported results for the second quarter of 2024.\nThe post TELO Stock Earnings: Telomir Pharmaceuticals...\n more…

Telomir Pharmaceuticals announces passing of CEO Christopher Chapman

Will Telomir Pharmaceuticals (NASDAQ:TELO) Spend Its Cash Wisely?

Simply Wall St We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...\n more…